Celltrion Sees ‘Record-High Revenue’ With Increasing Infliximab Sales

As Company Plans To Launch One Biological Product Every Year

 
• By Akriti Seth
  
Winning
Celltrion saw double-digit growth in Q4 FY21 • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products